Alexey Danilov, MD, PhD

The panel shares some final thoughts on unmet needs and the future of CLL treatment.

Dr Alexey Danilov explains data on emerging therapies, including anti-ROR1 therapies, BTK degrading agents, and bispecifics, for treatment of CLL.

The panel shares their thoughts on sequencing the available therapies in patients with CLL.

Dr Catherine Coombs explains the challenges of treating 17p deletions and Richter’s syndrome in patients with CLL and discusses the role of venetoclax in the treatment of these patients.

Seema Ali Bhat, MD, and Alexey Danilov, MD, PhD, discuss data updates on the use of fixed-duration venetoclax for the treatment of CLL.

Dr Seema Ali Bhat continues the conversation on non-covalent BTK inhibitors in CLL treatment with a look at nemtabrutinib and data from the BELLWAVE-001 study.

Catherine Coombs, MD, and Alexey Danilov, MD, PhD, discuss data on the investigational non-covalent BTK inhibitor pirtobrutinib for the treatment of CLL.

The panel explains the factors they consider when deciding on a BTK inhibitor for the treatment of patients with CLL.

Drs Susan O’Brien and Catherine Coombs describe the design and outcomes of the ELEVATE-RR and ALPINE trials that compare BTK inhibitors in CLL.

Seema Ali Bhat, MD, explains the SEQUOIA trial and the BTK inhibitor zanubrutinib for the frontline treatment of CLL, and Alexey Danilov, MD, PhD, describes the ASCEND trial that led to the approval of acalabrutinib for relapsed CLL.

Catherine Coombs, MD, reviews data on BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in the first-line treatment of CLL, and how she approaches selecting the appropriate BTK inhibitor in practice.

Susan O’Brien, MD, provides a brief overview of chronic lymphocytic leukemia (CLL), and Seema Ali Bhat, MD, explains the mechanism of BTK inhibitors.